TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03677726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Therapy for Insomnia
Description: The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
Study: NCT01843088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol cream
Description: 25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Study: NCT03677726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education Exercise Program
Description: The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
Study: NCT01575860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 10mg, oral tablets, daily
Study: NCT05256043

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes Diagnosis
Description: HbA1c \> 6.5%
Study: NCT01614756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164
Study: NCT01843088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Study: NCT03208868

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine enriched essential amino acid (EEA/LEU)
Description: Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced amino acid supplement (BAA)
Description: Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
Study: NCT01614756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164
Study: NCT01906385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium Liposome Treatment
Description: At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
Study: NCT02464371

Intervention type: OTHER
Intervention: kinetic of microRNAs
Description: blood samples will be drawn to measure microRNAs
Study: NCT03211858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog/NovoRapid
Description: NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
Study: NCT04638192

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
Study: NCT04360863

Intervention type: OTHER
Intervention: Telephone survey
Description: Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
Study: NCT02808871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone three times daily (2403 mg) for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for 52 weeks
Study: NCT03509610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study: NCT01614756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164
Study: NCT03211858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study: NCT03739671

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Group will receive 5000 units of vitamin D daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Vitamin D
Description: No vitamin D supplementation
Study: NCT03978481

Intervention type: COMBINATION_PRODUCT
Intervention: Helicobacter pylori eradication (combination therapy)
Description: Antibiotic eradication therapy (triple or quadriple regimen)
Study: NCT02675231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Single Agent Chemotherapy
Description: Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
Study: NCT04045301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab 16mg/kg
Description: Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab 8mg/kg
Description: Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-food oral immunotherapy (OIT)
Description: Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-food oral immunotherapy (OIT)
Description: Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multi-food oral immunotherapy (OIT)
Description: Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
Study: NCT02610569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard endoscopy
Description: standard endoscopy will be either colonoscopy or rectosigmoidoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCamCOLON (C2)
Description: PillCamCOLON (C2) is a colon video-capsule
Study: NCT03800693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study: NCT02904265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Study: NCT00592280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-Layer Method pancreas preservation system drug
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-Layer Method pancreas preservation system device
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
Study: NCT04859686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
Study: NCT03447691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Des (volatile anesthetic-desflurane)
Description: Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA (Total intravenous anesthesia with propofol and remifentanil)
Description: TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
Study: NCT03800693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV
Study: NCT04571073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model
Description: Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity.
Study: NCT03800693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT04723654

Intervention type: DEVICE
Intervention: Wireless Wearable Vital Sign Monitor
Description: Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours

Intervention type: DEVICE
Intervention: Wireless Wearable Vital Sign Monitor
Description: Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours
Study: NCT04189835

Intervention type: DIAGNOSTIC_TEST
Intervention: EBV DNA in whole blood and plasma
Description: Consecutive measurements of EBV DNA in whole blood and plasma
Study: NCT02839278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT00681018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid human milk fortifier
Description: Liquid human milk fortifier added to human milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Powder human milk fortifier
Description: Powder human milk fortifier added to human milk
Study: NCT04457115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane Block
Description: Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
Study: NCT02298387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83
Description: intravenous (in the vein) infusions
Study: NCT04521608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention- Home-based Pulmonary Rehabilitation
Description: Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
Study: NCT03707431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT
Description: The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
Study: NCT03833167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg
Description: Administered by IV infusion on Day 1 of each 42-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion on Day 1 of each 42-day cycle
Study: NCT01923818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: orally active direct factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: orally active direct factor Xa inhibitor
Study: NCT01180166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: 200 milligram (mg) of nimotuzumab per week during radiation period
Study: NCT00546468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy assisted distal gastrectomy
Description: under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open distal gastrectomy
Description: Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
Study: NCT02594241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl-Prednisolone
Description: Single-shot 125 mg infusion given immediately after induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Study: NCT03895021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pisando Fuerte
Description: Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\]).
Study: NCT01923818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: non-steroidal anti-inflammatory drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04792983

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no interventions.
Study: NCT00004136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Tumors heated to target temperature by electrodes for maximum of 20 minutes
Study: NCT01112462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg/Phenylephrine 5 mg tablets
Description: 2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 1000 mg/Phenylephrine 10 mg sachet
Description: 1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period